|
US5968965A
(en)
*
|
1996-01-30 |
1999-10-19 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
|
US6028201A
(en)
*
|
1996-01-30 |
2000-02-22 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
|
AU703203B2
(en)
*
|
1996-01-30 |
1999-03-18 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
|
EP1011669A4
(en)
*
|
1996-01-30 |
2001-09-12 |
Merck & Co Inc |
FARNESYL PROTEIN TRANSFERASE INHIBITORS
|
|
US5981562A
(en)
*
|
1996-01-30 |
1999-11-09 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
|
US6300501B1
(en)
|
1996-05-22 |
2001-10-09 |
Warner-Lambert Company |
Histidine-(N-benzyl glycinamide) inhibitors of protein farnesyl transferase
|
|
US6265382B1
(en)
*
|
1997-04-11 |
2001-07-24 |
Warner-Lambert Company |
Dipeptide inhibitors of protein farnesyltransferase
|
|
US6737410B1
(en)
|
1997-04-11 |
2004-05-18 |
Warner-Lambert Company |
Inhibitors of protein farnesyl transferase
|
|
US20030069231A1
(en)
|
1999-10-12 |
2003-04-10 |
Klaus Rudolf |
Modified aminoacids, pharmaceuticals containing these compounds and method for their production
|
|
NZ507165A
(en)
*
|
1998-04-27 |
2003-06-30 |
Warner Lambert Co |
Functionalized alkyl and alkenyl side chain derivatives of glycinamides as farnesyl transferase inhibitors
|
|
AU2477400A
(en)
|
1998-12-08 |
2000-06-26 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
|
WO2000034239A2
(en)
|
1998-12-08 |
2000-06-15 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
|
US6632818B2
(en)
|
2000-01-12 |
2003-10-14 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
|
JP2002188646A
(ja)
*
|
2000-12-20 |
2002-07-05 |
Nsk Ltd |
転がり軸受及び軸受装置
|
|
US7595312B2
(en)
|
2002-10-25 |
2009-09-29 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
|
|
WO2005049589A2
(en)
*
|
2003-10-14 |
2005-06-02 |
Cadila Healthcare Limited |
Heterocyclic compounds for the treatment of hyperlipidemia, diabetes, obesity and similar diseases
|
|
DE102004015723A1
(de)
|
2004-03-29 |
2005-10-20 |
Boehringer Ingelheim Pharma |
Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
|
ES2382814T3
(es)
|
2005-05-17 |
2012-06-13 |
Merck Sharp & Dohme Ltd. |
Ácido cis-4-[(4-clorofenil)sulfonil]-4-(2,5-difluorofenil)ciclohexanopropanoico para el tratamiento del cáncer
|
|
TW200804345A
(en)
|
2005-08-30 |
2008-01-16 |
Novartis Ag |
Substituted benzimidazoles and methods of preparation
|
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
|
EA018917B1
(ru)
|
2006-04-19 |
2013-11-29 |
Новартис Аг |
6-о-замещенные бензоксазолы и бензотиазолы и способы подавления передачи сигналов от csf-1r
|
|
WO2008039327A2
(en)
|
2006-09-22 |
2008-04-03 |
Merck & Co., Inc. |
Method of treatment using fatty acid synthesis inhibitors
|
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
|
AR064777A1
(es)
|
2007-01-10 |
2009-04-22 |
Inst Di Reserche D Biolog Mole |
Indazoles sustituidos con amida como inhibidores de poli (adp- ribosa) polimerasa (parp)
|
|
KR101514853B1
(ko)
|
2007-03-01 |
2015-04-24 |
노파르티스 아게 |
Ｐｉｍ 키나제 억제제 및 이들의 사용 방법
|
|
ES2452349T3
(es)
|
2007-05-21 |
2014-04-01 |
Novartis Ag |
Inhibidores de CSF-1R, composiciones, y métodos de uso
|
|
EP2170076B1
(en)
|
2007-06-27 |
2016-05-18 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
|
EP2413932A4
(en)
|
2009-04-01 |
2012-09-19 |
Merck Sharp & Dohme |
INHIBITORS OF AKT ACTIVITY
|
|
EP2440058A4
(en)
|
2009-06-12 |
2012-11-21 |
Dana Farber Cancer Inst Inc |
MELTED HETEROCYCLIC COMPOUNDS AND APPLICATIONS THEREOF
|
|
CA2777043C
(en)
|
2009-10-14 |
2015-12-15 |
Schering Corporation |
Substituted piperidines that increase p53 activity and the uses thereof
|
|
WO2011090738A2
(en)
|
2009-12-29 |
2011-07-28 |
Dana-Farber Cancer Institute, Inc. |
Type ii raf kinase inhibitors
|
|
EP2547661A2
(en)
|
2010-03-16 |
2013-01-23 |
Dana-Farber Cancer Institute, Inc. |
Indazole compounds and their uses
|
|
WO2011163330A1
(en)
|
2010-06-24 |
2011-12-29 |
Merck Sharp & Dohme Corp. |
Novel heterocyclic compounds as erk inhibitors
|
|
AU2011285909B2
(en)
|
2010-08-02 |
2016-11-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
|
|
US9029341B2
(en)
|
2010-08-17 |
2015-05-12 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
|
|
US8883801B2
(en)
|
2010-08-23 |
2014-11-11 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
|
|
WO2012030685A2
(en)
|
2010-09-01 |
2012-03-08 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
|
US9242981B2
(en)
|
2010-09-16 |
2016-01-26 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel ERK inhibitors
|
|
EP3766975A1
(en)
|
2010-10-29 |
2021-01-20 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
|
|
US9351965B2
(en)
|
2010-12-21 |
2016-05-31 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as ERK inhibitors
|
|
WO2012145471A1
(en)
|
2011-04-21 |
2012-10-26 |
Merck Sharp & Dohme Corp. |
Insulin-like growth factor-1 receptor inhibitors
|
|
US9023865B2
(en)
|
2011-10-27 |
2015-05-05 |
Merck Sharp & Dohme Corp. |
Compounds that are ERK inhibitors
|
|
US9382239B2
(en)
|
2011-11-17 |
2016-07-05 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of c-Jun-N-terminal kinase (JNK)
|
|
WO2013165816A2
(en)
|
2012-05-02 |
2013-11-07 |
Merck Sharp & Dohme Corp. |
SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
|
|
BR112015006990A2
(pt)
|
2012-09-28 |
2017-07-04 |
Merck Sharp & Dohme |
composto, composição farmacêutica, e, uso de pelo menos um composto
|
|
EP2909194A1
(en)
|
2012-10-18 |
2015-08-26 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
|
WO2014063054A1
(en)
|
2012-10-19 |
2014-04-24 |
Dana-Farber Cancer Institute, Inc. |
Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
|
|
WO2014063061A1
(en)
|
2012-10-19 |
2014-04-24 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
|
JP6290237B2
(ja)
|
2012-11-28 |
2018-03-07 |
メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． |
癌を処置するための組成物および方法
|
|
MX373639B
(es)
|
2012-12-20 |
2020-05-04 |
Merck Sharp & Dohme |
Imidazopiridinas sustituidas como inhibidores de doble minuto 2 humana.
|
|
EP2951180B1
(en)
|
2013-01-30 |
2018-05-02 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as hdm2 inhibitors
|
|
WO2015034925A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
|
JP6491202B2
(ja)
|
2013-10-18 |
2019-03-27 |
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド |
サイクリン依存性キナーゼ７（ｃｄｋ７）の多環阻害剤
|
|
CA2927917C
(en)
|
2013-10-18 |
2022-08-09 |
Syros Pharmaceuticals, Inc. |
Heteroaromatic compounds useful for the treatment of proliferative diseases
|
|
WO2015164614A1
(en)
|
2014-04-23 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Janus kinase inhibitors and uses thereof
|
|
US9862688B2
(en)
|
2014-04-23 |
2018-01-09 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged janus kinase inhibitors and uses thereof
|
|
JO3589B1
(ar)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
مثبطات كيناز البروتين c وطرق استخداماتها
|
|
WO2016105528A2
(en)
|
2014-12-23 |
2016-06-30 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
|
WO2016160617A2
(en)
|
2015-03-27 |
2016-10-06 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
|
AU2016276963C1
(en)
|
2015-06-12 |
2021-08-05 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
|
JP7028766B2
(ja)
|
2015-09-09 |
2022-03-02 |
ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド |
サイクリン依存性キナーゼの阻害剤
|
|
JOP20190055A1
(ar)
|
2016-09-26 |
2019-03-24 |
Merck Sharp & Dohme |
أجسام مضادة ضد cd27
|
|
EP3525785B1
(en)
|
2016-10-12 |
2025-08-27 |
Merck Sharp & Dohme LLC |
Kdm5 inhibitors
|
|
TWI841526B
(zh)
|
2017-04-13 |
2024-05-11 |
荷蘭商賽羅帕公司 |
抗-SIRPα 抗體
|
|
US10947234B2
(en)
|
2017-11-08 |
2021-03-16 |
Merck Sharp & Dohme Corp. |
PRMT5 inhibitors
|
|
US11098059B2
(en)
|
2017-11-08 |
2021-08-24 |
Merck Sharp & Dohme Corp. |
PRMT5 inhibitors
|
|
WO2019148412A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1/lag3 bispecific antibodies
|
|
CA3099763A1
(en)
|
2018-06-25 |
2020-01-02 |
Dana-Farber Cancer Institute, Inc. |
Taire family kinase inhibitors and uses thereof
|
|
US11993602B2
(en)
|
2018-08-07 |
2024-05-28 |
Merck Sharp & Dohme Llc |
PRMT5 inhibitors
|
|
EP3833667B1
(en)
|
2018-08-07 |
2024-03-13 |
Merck Sharp & Dohme LLC |
Prmt5 inhibitors
|
|
BR112021002267A8
(pt)
|
2018-08-07 |
2023-02-07 |
Merck Sharp & Dohme |
Inibidores de prmt5
|
|
US12281126B2
(en)
|
2018-12-28 |
2025-04-22 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 and uses thereof
|
|
AU2024228641A1
(en)
|
2023-03-02 |
2025-07-24 |
Carcimun Biotech Gmbh |
Means and methods for diagnosing cancer and/or an acute inflammatory disease
|